Action RXI PHARMACEUTICALS CORP
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués RXi Pharmaceuticals Corp OTC Bulletin Board

Actions

US74979C1053

Cours en clôture OTC Bulletin Board
Autres places de cotation
- USD - Graphique intraday de RXi Pharmaceuticals Corp
02/07 Le conseil d'administration de Phio Pharmaceuticals approuve un regroupement d'actions à raison de 1 pour 9 MT
28/05 Phio Pharmaceuticals Corp. annonce une recommandation positive du comité de surveillance de la sécurité de l'étude clinique de phase 1b du produit phare de Phio, le PH-762 CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
AQ
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
NE
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
AQ
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
NE
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
NE
Phio Pharmaceuticals Announces Reverse Stock Split
NE
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
NE
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
AQ
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
NE
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
NE
Phio Pharmaceuticals Secures New Investor
AQ
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
AQ
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
GL
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
AQ
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
AQ
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
AQ
National Spotlight Features Phio’s Innovative RNAi Technology Platform
AQ
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PHIO
  4. Action
  5. Actualités RXi Pharmaceuticals Corp
  6. Communiqués